Systematic Analysis of Coronavirus Disease 2019 (COVID-19) Receptor ACE2 in Malignant Tumors: Pan-Cancer Analysis

Jukun Song; Jing Han; Feng Liu; Xianlin Chen; Shenqi Qian; Yadong Wang; Zhenyu Jia; Xiaofeng Duan; Xiangyan Zhang; Jianguo Zhu

doi:10.3389/fmolb.2020.569414

Systematic Analysis of Coronavirus Disease 2019 (COVID-19) Receptor ACE2 in Malignant Tumors: Pan-Cancer Analysis

Front Mol Biosci. 2020 Oct 23:7:569414. doi: 10.3389/fmolb.2020.569414. eCollection 2020.

Authors

Jukun Song¹, Jing Han², Feng Liu³, Xianlin Chen¹, Shenqi Qian⁴, Yadong Wang¹, Zhenyu Jia⁵, Xiaofeng Duan¹, Xiangyan Zhang², Jianguo Zhu⁶

Affiliations

¹ Department of Oral and Maxillofacial Surgery, Guizhou Provincial People's Hospital, Guizhou, China.
² Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guizhou, China.
³ Department of B Ultrasound, Guizhou Provincial People's Hospital, Guizhou, China.
⁴ Department of Stomatology, Changshun County Medical Group Central Hospital, Guizhou, China.
⁵ Department of Botany and Plant Sciences, University of California, Riverside, Riverside, CA, United States.
⁶ Department of Urology, Guizhou Provincial People's Hospital, Guizhou, China.

Abstract

Background: Coronavirus disease 2019 (COVID-19) was first detected in patients with pneumonia in December 2019 in China and it spread rapidly to the rest of the world becoming a global pandemic. Several observational studies have reported that cancer is a risk factor for COVID-19. On the other hand, ACE2, a receptor for the SARS-CoV-2 virus, was found to be aberrantly expressed in many tumors. However, the characterization of aberrant ACE2 expression in malignant tumors has not been elucidated. Here, we conducted a systematic analysis of the ACE2 expression profile across 31 types of tumors.

Methods: Distribution of ACE2 expression was analyzed using the GTEx, CCLE, TCGA pan-cancer databases. We evaluated the effect of ACE2 on clinical prognosis using the Kaplan-Meier survival plot and COX regression analysis. Correlation between ACE2 and immune infiltration levels was investigated in various cancer types. Additionally, the correlation between ACE2 and immune neoantigen, TMB, microsatellite instability, Mismatch Repair Genes (MMRs), HLA gene members, and DNA Methyltransferase (DNMT) was investigated. The frequency of ACE2 gene mutation in various tumors was analyzed. Functional enrichment analysis was conducted in various cancer types using the GSEA method.

Results: In normal tissues, ACE2 was highly expressed in almost all 31 organs tested. In cancer cell lines, the expression level of ACE2 was low to medium. Although aberrant expression was observed in most cancer types, high expression of ACE2 was not linked to OS, DFS, RFS, and DFI in most tumors in TCGA pan-cancer data. We found that ACE2 expression was significantly correlated with the infiltrating levels of macrophages and dendritic cells, CD4+ T cells, CD8+ T cells, and B cells in multiple tumors. A positive correlation between ACE2 expression and immune neoantigen, TMB, and microsatellite instability was found in multiple cancers. GSEA analysis which was carried out to determine the effect of ACE2 on tumors indicated that several cancer-associated pathways and immune-related pathways were hyperactivated in the high ACE2 expression group of most tumors.

Conclusion: These findings suggest that ACE2 is not correlated with prognosis in most cancer types. However, elevated ACE2 is significantly correlated with immune infiltrating levels, including those of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in multiple cancers, especially in lung and breast cancer patients. These findings suggest that ACE2 may affect the tumor environment in cancer patients with COVID-19.

Keywords: ACE2; COVID-19; Pan-cancer analysis; SARS-CoV-2; TCGA.